159 related articles for article (PubMed ID: 37871898)
1. The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
Choi MG; Kim YJ; Lee JC; Ji W; Oh IJ; Lee SY; Yoon SH; Lee SY; Lee JE; Kim EY; Choi CM
Cancer Res Treat; 2024 Apr; 56(2):422-429. PubMed ID: 37871898
[TBL] [Abstract][Full Text] [Related]
2. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis.
Chen H; Ma X; Liu J; Yang Y; He Y; Fang Y; Wang L; Fang J; Zhao J; Zhuo M
Clin Transl Oncol; 2024 Jul; 26(7):1664-1673. PubMed ID: 38329610
[TBL] [Abstract][Full Text] [Related]
3. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
[TBL] [Abstract][Full Text] [Related]
6. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
7. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
[TBL] [Abstract][Full Text] [Related]
8. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
Agarwal M; Liu A; Langlais BT; Leventakos K; Yu NY; Almquist D; Manochakian R; Ernani V
Clin Lung Cancer; 2023 Nov; 24(7):591-597. PubMed ID: 37365076
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
Gürbüz M; Kutlu Y; Akkuş E; Köksoy EB; Köse N; Öven BB; Uluç BO; Demiray AG; Erdem D; Demir B; Turhal NS; Üskent N; Akbaş S; Selçukbiricik F; İnal A; Bilici A; Ölmez ÖF; Çabuk D; Ünal Ç; Hızal M; Şendur MAN; Korkmaz M; Karadurmuş N; Ertürk İ; Göksu SS; Tatlı AM; Güven DC; Kılıçkap S; Paksoy N; Aydıner A; Çınkır HY; Özkul Ö; Öztürk A; Ballı S; Kemal Y; Erdoğan AP; Er Ö; Yumuk PF; Demirkazık A
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3547-3555. PubMed ID: 35689097
[TBL] [Abstract][Full Text] [Related]
11. Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133).
Nishio M; Sugawara S; Atagi S; Akamatsu H; Sakai H; Okamoto I; Takayama K; Hayashi H; Nakagawa Y; Kawakami T
Clin Lung Cancer; 2019 Nov; 20(6):469-476.e1. PubMed ID: 31466854
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
13. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
[TBL] [Abstract][Full Text] [Related]
14. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.
Qi WX; Xiang Y; Zhao S; Chen J
Cancer Immunol Immunother; 2021 Nov; 70(11):3199-3206. PubMed ID: 33796915
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience.
Lee S; Shim HS; Ahn BC; Lim SM; Kim HR; Cho BC; Hong MH
Cancer Immunol Immunother; 2022 May; 71(5):1093-1101. PubMed ID: 34568975
[TBL] [Abstract][Full Text] [Related]
16. Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis.
Chen J; Wang J; Xu H
Medicine (Baltimore); 2021 Apr; 100(15):e25180. PubMed ID: 33847617
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Wang BC; Fu C; Lin GH
Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
